Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Temporal validation of a risk prediction model for breast cancer‐related lymphoedema in European population: A retrospective study

Temporal validation of a risk prediction model for breast cancer‐related lymphoedema in European... INTRODUCTIONLymphoedema is a common complication arising from treatment for breast cancer (Marchica et al., 2021), and it can be physically debilitating and severely undermine patients' quality of life (Anbari et al., 2021). Breast cancer‐related lymphoedema (BCRL) may also impact negatively a woman's psychological well‐being and self‐image, leading to anxiety and depressive symptoms and seriously affecting work and family life (Vignes et al., 2020).Some estimates suggest that one in five women develop lymphoedema following treatment for breast cancer (DiSipio et al., 2013), although the reported incidence varies widely, from 0.2% to 39.4%, depending on the type of treatment received (Byun et al., 2022; Lin et al., 2021; Shah et al., 2021). Byun et al. (2022) found that lymphoedema rates differed depending on time to follow up, and they identified body mass index (BMI), the number of lymph nodes removed and taxane‐based chemotherapy as risk factors, among others.Identifying the risk factors for BCRL is essential for designing adequate prevention strategies and care plans.BACKGROUNDThe most recent consensus document of the International Society of Lymphology lists higher BMI, more extensive lymph node dissection, more extensive surgical procedures, receipt of adjuvant therapy (including radiotherapy or chemotherapy) and a sedentary lifestyle as being more firmly supported as risk factors for lymphoedema (International Society http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Advanced Nursing Wiley

Temporal validation of a risk prediction model for breast cancer‐related lymphoedema in European population: A retrospective study

Loading next page...
 
/lp/wiley/temporal-validation-of-a-risk-prediction-model-for-breast-cancer-ugPy8ZfcPe

References (31)

Publisher
Wiley
Copyright
© 2023 John Wiley & Sons Ltd.
ISSN
0309-2402
eISSN
1365-2648
DOI
10.1111/jan.15727
Publisher site
See Article on Publisher Site

Abstract

INTRODUCTIONLymphoedema is a common complication arising from treatment for breast cancer (Marchica et al., 2021), and it can be physically debilitating and severely undermine patients' quality of life (Anbari et al., 2021). Breast cancer‐related lymphoedema (BCRL) may also impact negatively a woman's psychological well‐being and self‐image, leading to anxiety and depressive symptoms and seriously affecting work and family life (Vignes et al., 2020).Some estimates suggest that one in five women develop lymphoedema following treatment for breast cancer (DiSipio et al., 2013), although the reported incidence varies widely, from 0.2% to 39.4%, depending on the type of treatment received (Byun et al., 2022; Lin et al., 2021; Shah et al., 2021). Byun et al. (2022) found that lymphoedema rates differed depending on time to follow up, and they identified body mass index (BMI), the number of lymph nodes removed and taxane‐based chemotherapy as risk factors, among others.Identifying the risk factors for BCRL is essential for designing adequate prevention strategies and care plans.BACKGROUNDThe most recent consensus document of the International Society of Lymphology lists higher BMI, more extensive lymph node dissection, more extensive surgical procedures, receipt of adjuvant therapy (including radiotherapy or chemotherapy) and a sedentary lifestyle as being more firmly supported as risk factors for lymphoedema (International Society

Journal

Journal of Advanced NursingWiley

Published: Dec 1, 2023

Keywords: breast cancer; breast cancer‐related lymphoedema; nursing; prediction model; risk; risk factors; ROC curve; secondary lymphoedema; temporal validation; tool

There are no references for this article.